BR112012030816A2 - agentes antiinflamatórios - Google Patents

agentes antiinflamatórios

Info

Publication number
BR112012030816A2
BR112012030816A2 BR112012030816A BR112012030816A BR112012030816A2 BR 112012030816 A2 BR112012030816 A2 BR 112012030816A2 BR 112012030816 A BR112012030816 A BR 112012030816A BR 112012030816 A BR112012030816 A BR 112012030816A BR 112012030816 A2 BR112012030816 A2 BR 112012030816A2
Authority
BR
Brazil
Prior art keywords
inflammatory agents
compounds
formulas
aromatic
preventing
Prior art date
Application number
BR112012030816A
Other languages
English (en)
Inventor
David John Fox
David John Grainger
Original Assignee
Boehringer Ingelheim Int
Cambridge Entpr Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42471347&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112012030816(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int, Cambridge Entpr Ltd filed Critical Boehringer Ingelheim Int
Publication of BR112012030816A2 publication Critical patent/BR112012030816A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D223/12—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C07D211/76—Oxygen atoms attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

agentes antiinflamatórios. são revelados aqui métodos de previnir ou tratar doenças inflamatórias utilizando compostos de 3-aminolactama, cada um com "grupos de cauda" aromáticos. os compostos como definidos pelas fórmulas (i) e (i<39>) e os usos médicos dos compostos, são descritos aqui.
BR112012030816A 2010-06-08 2011-06-08 agentes antiinflamatórios BR112012030816A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1009603.0A GB201009603D0 (en) 2010-06-08 2010-06-08 Anti-inflammatory agent
PCT/GB2011/000863 WO2011154696A1 (en) 2010-06-08 2011-06-08 Anti-inflammatory agents

Publications (1)

Publication Number Publication Date
BR112012030816A2 true BR112012030816A2 (pt) 2016-11-01

Family

ID=42471347

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112012030816A BR112012030816A2 (pt) 2010-06-08 2011-06-08 agentes antiinflamatórios
BR112012031136A BR112012031136A2 (pt) 2010-06-08 2011-06-08 agentes anti-inflamatórios

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR112012031136A BR112012031136A2 (pt) 2010-06-08 2011-06-08 agentes anti-inflamatórios

Country Status (20)

Country Link
US (2) US20130203734A1 (pt)
EP (2) EP2580196A1 (pt)
JP (2) JP2013531647A (pt)
KR (2) KR20130086952A (pt)
CN (2) CN103119021A (pt)
AP (2) AP2012006560A0 (pt)
AU (1) AU2011263531A1 (pt)
BR (2) BR112012030816A2 (pt)
CA (2) CA2798129A1 (pt)
CL (1) CL2012003460A1 (pt)
CO (2) CO6670553A2 (pt)
GB (1) GB201009603D0 (pt)
IL (2) IL222798A0 (pt)
MA (2) MA34369B1 (pt)
MX (2) MX2012014291A (pt)
PE (2) PE20130772A1 (pt)
SG (2) SG185130A1 (pt)
TN (2) TN2012000521A1 (pt)
WO (2) WO2011154696A1 (pt)
ZA (2) ZA201208367B (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201992341A8 (ru) * 2017-09-07 2020-08-11 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Применение производного глутаримида для лечения заболеваний, связанных с аберрантной активностью цитокинов

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3054738B2 (ja) * 1988-07-22 2000-06-19 武田薬品工業株式会社 チアゾロ［５，４―ｂ］アゼピン誘導体
JPH03206042A (ja) 1990-01-06 1991-09-09 Takeda Chem Ind Ltd 降圧剤
IT1247698B (it) 1990-06-21 1994-12-30 Sigma Tau Ind Farmaceuti 1-alchil-3-(acilammino)-e-caprolattami quali attivatori dei processi di apprendimento e della memoria e composizioni farmaceutiche comprendenti tali composti
DE4117507A1 (de) 1991-05-24 1992-11-26 Schering Ag Verfahren zur herstellung von n(pfeil hoch)6(pfeil hoch)-substituierten lysin-derivaten
JP3206042B2 (ja) 1991-10-31 2001-09-04 ミノルタ株式会社 新規トリアミノ化合物を用いた電荷輸送材料、このトリアミノ化合物を含有する感光体およびエレクトロルミネセンス素子
US6989435B2 (en) 1997-09-11 2006-01-24 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
WO2000042071A2 (en) 1999-01-12 2000-07-20 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
AU2003269850A1 (en) * 2002-10-08 2004-05-04 Novo Nordisk A/S Hemisuccinate salts of heterocyclic dpp-iv inhibitors
AU2004224807A1 (en) * 2003-03-24 2004-10-07 Axikin Pharmaceuticals, Inc. 2-phenoxy- and 2-phenylsulfomamide derivatives with CCR3 antagonistic activity for the treatment of asthma and other inflammatory or immunological disorders
NZ547528A (en) 2003-10-29 2008-11-28 Elan Pharm Inc N-substituted benzene sulfonamides
SI1691814T1 (sl) * 2003-12-01 2012-11-30 Cambridge Entpr Ltd Protivnetna zdravila
EP1768960A1 (en) * 2004-07-13 2007-04-04 F.Hoffmann-La Roche Ag Sulfonamide derivatives
GB2418425B (en) 2004-08-11 2008-09-03 Univ Cambridge Tech Anti-inflammatory agents
GB2418426A (en) 2004-08-18 2006-03-29 Univ Cambridge Tech Alpha-(acylamino)-bicyclolactam derivatives for treatment of inflammatory disorders
GB2423085C (en) 2005-02-11 2011-11-09 Cambridge Entpr Ltd Ligands for G-protein coupled receptors
GB0512238D0 (en) 2005-06-15 2005-07-27 Univ Cambridge Tech Anti-inflammatory agents
EP1896036B1 (en) * 2005-06-15 2013-01-23 Cambridge Enterprise Limited Anti-inflammatory agents
AU2006281493A1 (en) 2005-08-12 2007-02-22 F. Hoffmann-La Roche Ag Fluoro substituted 2-oxo azepan derivatives
NZ566862A (en) 2005-09-27 2010-12-24 Irm Llc Diarylamine-containing compounds and compositions, and their use as modulators of C-kit receptors
JP2010534652A (ja) 2007-07-26 2010-11-11 イプセン ファルマ ソシエテ パ アクシオンス シンプリフィエ ケモカイン類似体
GB2452696B (en) 2007-08-02 2009-09-23 Cambridge Entpr Ltd 3-(2',2'-dimethylpropanoylamino)-tetrahydropyridin-2-one and its use in pharmaceutical compositions

Also Published As

Publication number Publication date
AP2012006560A0 (en) 2012-12-31
IL222866A0 (en) 2012-12-31
SG185129A1 (en) 2012-12-28
CA2798213A1 (en) 2011-12-15
WO2011154696A1 (en) 2011-12-15
BR112012031136A2 (pt) 2017-08-08
US20130203734A1 (en) 2013-08-08
CO6670569A2 (es) 2013-05-15
PE20130772A1 (es) 2013-07-03
TN2012000521A1 (en) 2014-04-01
CO6670553A2 (es) 2013-05-15
EP2580196A1 (en) 2013-04-17
CN103080090A (zh) 2013-05-01
PE20131046A1 (es) 2013-09-23
ZA201208367B (en) 2013-10-30
MX2012014291A (es) 2013-05-01
JP2013528201A (ja) 2013-07-08
KR20130115082A (ko) 2013-10-21
CL2012003460A1 (es) 2013-08-16
TN2012000525A1 (en) 2014-04-01
JP2013531647A (ja) 2013-08-08
WO2011154695A1 (en) 2011-12-15
KR20130086952A (ko) 2013-08-05
CA2798129A1 (en) 2011-12-15
IL222798A0 (en) 2012-12-31
MX2012014290A (es) 2013-05-01
MA34370B1 (fr) 2013-07-03
CN103119021A (zh) 2013-05-22
ZA201208406B (en) 2013-07-31
US20130172318A1 (en) 2013-07-04
EP2580197A1 (en) 2013-04-17
MA34369B1 (fr) 2013-07-03
AU2011263531A1 (en) 2012-11-22
GB201009603D0 (en) 2010-07-21
AP2012006559A0 (en) 2012-12-31
SG185130A1 (en) 2012-12-28

Similar Documents

Publication Publication Date Title
CY1120337T1 (el) Θειοοξικες ενωσεις, συνθεσεις και μεθοδοι χρησης
BR112018012756A2 (pt) compostos heterocíclicos como imunomoduladores
BR112017011923A2 (pt) bactéria modificada para tratar doenças associadas com hiperamonemia
EA201590850A1 (ru) Трициклические конденсированные производные тиофена как ингибиторы jak
BR112015018508A2 (pt) moduladores de enzimas modificadoras de metila, suas composições e uso
BR112014026703A2 (pt) inibidores de dna-pk
EA201490042A1 (ru) Азетидинил-фенил-, пиридил- или пиразинилкарбоксамидные производные как ингибиторы jak
CO6620050A2 (es) Derivados de aminopirimidina como moduladores de la lrrk2
BR112015024078A2 (pt) derivados de benzimidazolona como inibidores de bromodomínio
CR20130588A (es) Halogenoalquil-1,3-oxazinas como inhibidores de la bace1 y/o bace 2
ECSP13013024A (es) 1,3-oxazinas como inhibidores de bace1 y/o bace2
BR112012020558A2 (pt) moduladores do receptor de androgênio e seus usos
BRPI0808775A2 (pt) compostos e composições como moduladores de atividade de gpr119
MA32811B1 (fr) Nouveaux composés
BR112015022462A8 (pt) inibidores de ido, composição farmacêutica, método de inibição de atividade de indolamina 2,3-dioxigenase e uso dos referidos inibidores
EA201201648A1 (ru) Стимуляторы sgc
CR20130432A (es) 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2
MA33939B1 (fr) 5-alcynyl-pyrimidines
DOP2010000304A (es) Composiciones y metodos de preparacion y uso de las mismas
BR112014005487A2 (pt) composições iodopovidona estáveis
BR112015006524A2 (pt) derivados de quinazolinona como inibidores de parp
BR112017012504A2 (pt) derivados de piperidina como inibidores de hdac1/2
ECSP17010481A (es) Novedosas pirimidinas 2,5-sustituidas
MA32723B1 (fr) Derives d&#39;anilino-pyrimidine a substitution sulfoximine en tant qu&#39;inhibiteurs de cdk, leur preparation et leur utilisation comme medicaments
BR112018071602A2 (pt) compostos de imidazopiridina substituídos como inibidores da indolamina 2,3-dioxigenase e/ou triptofano-2,3-dioxigenase

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]